Immunomedics, UCB restructure Phase III candidate epratuzumab licence agreement
This article was originally published in Scrip
Executive Summary
Immunomedics is to gain an up front payment of $30 million from UCB, following an amendment to the 2006 deal that gave the Belgian pharma company exclusive worldwide rights to develop and commercialise Immunomedics' humanised CD22 antibody epratuzumab for all autoimmune disease indications.